Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pain Therapeutics has reported positive results from a phase I trial evaluating PTI-202 the company's second abuse-resistant opioid painkiller.
Subscribe to our email newsletter
This clinical trial was designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of a single dose of PTI-202 in healthy volunteers. Pain Therapeutics believes the results also indicate PTI-202 is safe and well-tolerated and its release profile appears well-suited for use with a chronic pain population. There were no unexpected adverse events in this trial.
“These results in healthy volunteers nicely recapitulate what we previously observed in animal studies and provide further evidence that the underlying abuse-resistant platform can be applied across different opioid painkillers.” said Remi Barbier, president and CEO.
PTI-202 is intended to meet the needs of physicians who appropriately prescribe opioid painkillers and who seek to minimize the risks of drug diversion, abuse or accidental patient misuse.